BL22

A 63-kDa anti-CD22 recombinant immunotoxin, containing truncated Pseudomonas exotoxin and variable domains from an anti-CD22 antibody. It was effective against hairy cell leukaemia in phase-II trials of patients who had relapse less than 4 years after cladribine therapy.

References in periodicals archive

Bergeron et al., "Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia," The New England Journal of Medicine, vol.

EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway

Browning still offers their slick little BL22 and Marlin at least catalogs a 24-inch barreled Model 39A (which at this writing seems to be unavailable).

Indisputably indispensable: Henry's small game rifle is a lever-lover's .22

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

Quantification of diphtheria toxin-mediated ADP-ribosylation in a solid-phase assay

A genetically engineered drug known as BL22 has sent a type of cancer called hairy cell leukemia into full remission in 11 of 16 patients, a study shows.

The findings, reported in the July 26 NEW ENGLAND JOURNAL OF MEDICINE, suggest that BL22 may become a treatment for this type of leukemia.

The other three had their cancer recur within 16 months of being treated with BL22 but then were successfully treated again, Kreitman says.

New drug fights a chronic leukemia

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.